ema semaglutide naion very rare side effect side effect - NAIONMounjaro NAION is a very rare side effect of semaglutide meds Understanding the Very Rare Side Effect of NAION with Semaglutide

Semaglutideeye problems The widely used GLP-1 agonist, semaglutide, known for its effectiveness in managing type 2 diabetes and promoting weight loss through medications like Ozempic, Rybelsus, and Wegovy, has been associated with a very rare side effect impacting visionOther safety alerts - 2025-01-18 (1). This very rare side effect, identified as non-arteritic anterior ischemic optic neuropathy (NAION), has been the subject of review and confirmation by the European Medicines Agency (EMA) and its safety committee, the PRAC (Pharmacovigilance Risk Assessment Committee).Ozempic and other weight-loss drugs linked to sudden vision ...

What is NAION and its Connection to Semaglutide?

NAION is an eye condition that occurs when blood flow to the optic nerve is interrupted. This interruption can lead to swelling and damage to the optic nerve, potentially causing a sudden and permanent loss of vision. The EMA and PRAC have concluded, following extensive literature reviews and assessments, that NAION is a very rare side effect of semaglutide. This means that while the risk is exceptionally low, it is a recognized potential outcome for individuals using semaglutide medications.2025年6月21日—Non-arteritic anterior ischaemic optic neuropathy (NAION), an eye disorder which may cause loss of vision, is avery rare side effectof ...

The EMA's findings suggest that NAION may affect up to 1 in 10,000 users of semaglutide. This classification of "very rare" is crucial when understanding the risk-benefit profile of these medications.Eye Condition a 'Very Rare' Side Effect of Semaglutide, ... While the possibility exists, it is statistically infrequent. The PRAC has recommended that the product information for semaglutide be updated to include NAION as a very rare side effect2025年6月11日—The weekly injections may, invery rarecases, cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee .... This update aims to ensure healthcare professionals and patients are fully apprised of all potential risks.

Evidence and Regulatory Stance

The confirmation of NAION as a very rare side effect of semaglutide drugs is a significant development. The EMA’s formal recognition of this association has implications for ongoing discussions and, in some cases, litigation.Novo's Ozempic linked to rare cases of serious eye ... Data from clinical trials has also indicated a slightly elevated risk of NAION in patients taking semaglutide compared to those on a placebo. Some studies have even shown a higher cumulative incidence of NAION over 36 months for individuals on semaglutide (6.7%) compared to those not on the medication (0.8%), particularly in individuals who are overweight or obese2025年7月15日—literature, PRAC has concluded thatNAION is a very rare side effect of semaglutide. (meaning it may affect up to 1 in 10,000 people taking ....

It is important for patients to understand that even with these findings, the overall risk for NAION remains low, even among those on semaglutide.PRAC concludes eye condition NAION is a very rare side ... The EMA's review determined that while NAION may affect a small number of individuals, it is a recognized potential harm. The EMA has recommended that the semaglutide's safety information be updated to reflect this, listing NAION as a "very rare" occurrence.

Recognizing Symptoms and Seeking Medical Advice

Given that NAION can lead to vision loss, it is essential for patients using semaglutide to be aware of potential symptoms. Any sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide should be immediately reported to a healthcare professional. Prompt medical attention is crucial for eye conditions, and while NAION's reversibility can vary, early intervention is always advisable2025年6月6日—The committee - PRAC has concluded thatNAION is a very rare side effect of semaglutide. EMA has recommended that the product information for ....

The EMA has officially confirmed that NAION is "a very rare" side effect of semaglutide drugs, underscoring the importance of vigilance. This official acknowledgment from a regulatory body like the EMA provides a clear understanding of the recognized risks associated with these medications.

Key Takeaways for Patients and Healthcare Providers:

* NAION is now officially recognized by the EMA as a very rare side effect of semaglutide.2025年6月21日—Non-arteritic anterior ischaemic optic neuropathy (NAION), an eye disorder which may cause loss of vision, is avery rare side effectof ...

* This rare eye condition may affect up to 1 in 10,000 individuals using semaglutide (Ozempic, Rybelsus, Wegovy).EU Drug Regulator Finds 'Very Rare' Ozempic Link to ...

* Patients experiencing sudden vision changes should contact their doctor immediately.

* The side effect is listed as "very rare" in the updated semaglutide's safety information.4小时前—In June 2025, the European Medicines Agency updatedsemaglutide's safety information, listing NAION as a “very rare” side effect. The EMA ...

* While a potential risk, the incidence of NAION remains exceptionally low, and the benefits of semaglutide for diabetes and weight management are significant for many individuals.

It is vital for patients to engage in open communication with their healthcare providers regarding any concerns about semaglutide and its potential side effects, including NAION.2025年8月11日—In June, the European Medicines Agency concludedNAION represented a “very rare” side effect of semaglutide medications: a one in 10,000 chance. This collaborative approach ensures informed decision-making and the best possible health outcomes. The EMA's review process, including the PRAC meeting highlights, aims to provide accurate and up-to-date safety information for all medications.2025年6月6日—Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare”side effectof treatment with the glucagon-like ...